-
RBC Lifts Stryker Price Target, Says Medtech Company Positioned For Growth
Monday, March 11, 2019 - 1:50pm | 335Read More...Meetings with Stryker Corporation’s (NYSE: SYK) CEO inspired greater confidence in the company’s topline growth being sustainable into the foreseeable future, as well as near- and medium-term cost-saving opportunities, according to RBC Capital Markets. The Analyst RBC Capital Markets...
-
Analysts Unfazed By Intuitive Surgical's Higher Opex Guidance
Friday, January 25, 2019 - 12:20pm | 530Read More...Intuitive Surgical, Inc. (NASDAQ: ISRG) reported Thursday after the market close with higher fourth-quarter non-GAAP earnings per share — which fell short of expectations — and revenue that was slightly ahead of estimates. The Analysts Morgan Stanley analyst David Lewis...
-
The Surgical Robotics Revolution Isn't Slowing Down Any Time Soon, Says RBC Analyst
Monday, October 19, 2015 - 1:11pm | 394Read More...Brandon Henry of RBC Capital Markets estimated that U.S. robotic general surgery volumes rose sequentially in the third quarter. Henry noted that around 93 percent of U.S. robotic surgeons he surveyed indicated their third-quarter robotic volumes were flat or up sequentially. Henry added his...
-
UPDATE: RBC Capital Markets Downgrades Baxter International
Tuesday, January 7, 2014 - 12:03pm | 166Read More...In a report published Tuesday, RBC Capital Markets analyst Brandon Henry downgraded Baxter International (NYSE: BAX) to Sector Perform from Outperform, keeping its $73.00 price target. According to the report, it is expected that longer-acting products are to be a "game changer" for the...
-
UPDATE: RBC Capital Markets Upgrades Johnson & Johnson
Tuesday, January 7, 2014 - 11:50am | 278Read More...In a report published Tuesday, RBC Capital Markets analyst Brandon Henry upgraded Johnson & Johnson (NYSE: JNJ) to Outperform from Sector Perform, raising its price target from $88.00 to $104.00. According to the report, JNJ's pharmaceutical franchise should continue to deliver above industry...
-
UPDATE: RBC Capital Markets Upgrades St. Jude Medical
Tuesday, January 7, 2014 - 11:38am | 263Read More...In a report published Tuesday, RBC Capital Markets analyst Brandon Henry upgraded St. Jude Medical (NYSE: STJ) from Underperform to Sector Perform, raising its price target from $44.00 to $64.00. According to the report, the upgrade was based on the results of the analyst's Dec. 2013 EP survey....
-
RBC Capital Markets Raises Stryker Corporation (SYK) Price Target To $60
Wednesday, March 24, 2010 - 11:23am | 136Read More...RBC Capital Markets analysts Glen Novarro, Brandon Henry and Ross Comeaux maintained their Outperform rating for shares of Stryker Corporation (NYSE: SYK) and raised the price target from $57 to $60. The analysts said that the compliance overhang was abating, as Stryker Corporation resolved its...
